Cannabinoid Hyperemesis Syndrome: Why Standard Anti-Nausea Drugs Fail and What Works Instead | Research

The takeaway

Standard antiemetics commonly fail in cannabinoid hyperemesis syndrome, but benzodiazepines, antipsychotics, and topical capsaicin show promise based on the condition's unique pathophysiology.

Emergency physicians, cannabis users experiencing cyclical vomiting, urgent care providers.

Standard antiemetics commonly fail in CHS; benzodiazepines, antipsychotics, and capsaicin work through different mechanisms.

What the researchers found

CHS may result from the endocannabinoid system being overwhelmed by chronic cannabis use, with acute episodes triggered by stress or fasting. Standard antiemetics often fail because CHS involves different pathways than typical nausea. Benzodiazepines and antipsychotics work through their sedating effects, while capsaicin activates TRPV1 receptors through an entirely different mechanism.

Why it matters

CHS is increasingly common as cannabis potency and use rise, and patients often make repeated ER visits because standard treatments do not work. Understanding why and which alternatives are effective can reduce suffering and healthcare costs.

The numbers in context

CHS has become more prevalent with increasing cannabis potency and legalization. Treatment failure with standard antiemetics is common. Capsaicin, benzodiazepines, and antipsychotics represent the three main alternative treatment approaches.

How the study worked

Review of CHS pathophysiology and published literature on pharmacologic treatment in the emergency department setting.

What this study cannot tell us

Limited high-quality research despite increasing CHS prevalence. Most treatment evidence comes from case reports and case series rather than controlled trials. The exact mechanism of CHS remains incompletely understood.

How to read the evidence

Moderate - well-reasoned mechanistic review, but treatment evidence is largely from case reports rather than controlled trials.

When this study was published

Published in 2018. CHS treatment research has expanded since.

The bigger picture

CHS illustrates the principle that the endocannabinoid system has limits. Chronic overstimulation can fundamentally disrupt the body's stress response and homeostatic mechanisms. As cannabis potency continues to increase, CHS may become even more common.

Questions still open

What level of cannabis use triggers CHS? Why do some heavy users develop it while others do not? Could genetic factors determine susceptibility? Is there a role for preventive treatment in high-risk users?

Common questions

Why don't regular anti-nausea drugs work for CHS?

CHS involves disruption of the endocannabinoid system's regulation of stress and homeostasis, which is different from the pathways targeted by standard antiemetics. That's why alternative approaches like benzodiazepines and capsaicin are more effective.

What causes cannabinoid hyperemesis syndrome?

The review suggests CHS occurs when chronic cannabis use overwhelms the endocannabinoid system, which normally regulates stress response. Acute episodes may be triggered by stress or fasting in chronic users with already-disrupted hormonal feedback systems.

Read the original research

Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatment in the Emergency Department.

The Journal of emergency medicine, 54(3), 354-363

View on PubMed ↗Publisher’s paper ↗

Citation

Richards, John R. (2018). Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatment in the Emergency Department.. The Journal of emergency medicine, 54(3), 354-363. https://doi.org/10.1016/j.jemermed.2017.12.010